Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers

Breast Cancer Research and Treatment

Volumn 83, Issue 1, 2004, Pages 91-93

  Broeks, Annegien ^a   De Witte, Lot ^a   Nooijen, Anke ^a   Huseinovic, Angelina ^a   Klijn, Jan G M ^b   Van Leeuwen, Flora E ^a   Russell, Nicola S ^a   Van't Veer, Laura J ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; CHEK2; Contralateral; Mutation; Radiation

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CONTROLLED STUDY; DISEASE CARRIER; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GERM LINE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; PRIORITY JOURNAL; RADIATION INJURY; SECOND CANCER; TREATMENT OUTCOME;

ADULT; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MIDDLE AGED; NETHERLANDS; PROTEIN-SERINE-THREONINE KINASES;

EID: 0942279575     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000010697.49896.03     Document Type: Article

References (14)

1. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L et al.: A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749-1753, 1995
2. Matsuoka S, Huang M, Elledge SJ: Linkage of ATM to Cell Cycle regulation by the Chk2 protein kinase. Science 282: 1893-1897, 1998
3. Canman CE, Lim DS, Cimprich KA, Taya Y, Sakaguchi K, Appella E et al.: Activation of the ATM kinase by ionizing radiation an phosphorylation of p53. Science 11: 1677-1679, 1998
4. Bell DW, Varley J, Szydlo TE, Kang DH, Doke CRW: Heterozygous germline hCHK2 mutations in Li-Fraumeni syndrome. Science 286: 2528-2531, 1999
5. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O et al.: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71: 432-438, 2002
6. Offit K, Pierce H, Kirchhoff T, Kolachana P, Rapaport B, Gregersen P et al.: Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 4: 1, 2003
7. Sodha N, Bullock S, Taylor R, Mitchell G, Guertl-Lackner B, Williams RD et al.: CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer 87: 1445-1448, 2002
8. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R et al.: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31: 55-59, 2002
9. Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG et al.: Variants in CHEK2 Other than 1100delC Do Not Make a Major Contribution to Breast Cancer Susceptibility. Am J Hum Genet 72: 1023-1028, 2003
10. Adami HO, Bergstrom R, Hansen J: Age at first primary as a determinant of the incidence of bilateral breast cancer: Cumulative and relative risks in a population-based case-control study. Cancer 55: 643, 1985
11. Boice Jr JD, Harvey EB, Blettner M, Stovall M, Flannarry JT: Cancer in the contralateral breast after radiotherapy for breast cancer. N Eng J Med 326: 1357-1358, 1992
12. Boice Jr JD, Storm HH, Curtis RE, OM Jensen, Kleinerman RA, Jensen HS et al.: Introduction to the study of multiple primary cancers. Natl Cancer Inst Monogr 68: 3, 1985
13. Fraass BA, Robertson PL, Lichter AS: Dose to the contralateral breast due to primary breast irradiation. Int J Radiat Oncol Biol Phys 11: 485, 1985
14. Tercilla O, Krasin F, Lawn-Tsao L: Comparison of contralateral breast doses from beam block and isocentric treatment techniques for patient treated with primary breast irradiation with 60Co. Int J Radiat Oncol Biol Phys 17: 205, 1989